Drug Trial Radar · NCT06179160
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
710
Planned (sponsor's estimate)
Start
Jan 4, 2024
Primary completion
Jan 1, 2027
Study completion Jan 1, 2027
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Dec 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Conditions
- Solid Tumors
Interventions
INCB161734Drug
INCB161734 will be administered at protocol defined dose.
CetuximabDrug
Cetuximab will be administered at protocol defined dose.
RetifanlimabDrug
Retifanlimab will be administered at protocol defined dose.
GEMNabPDrug
GEMNabP will be administered at protocol defined dose.
mFOLFIRINOXDrug
mFOLFIRINOX will be administered at protocol defined dose.
FOLFOXDrug
FOLFOX will be administered at protocol defined dose.
FOLFIRIDrug
FOLFIRI will be administered at protocol defined dose.
INCA33890Drug
INCA33890 will be administered at protocol defined dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
- Number of participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 2 years and 90 days
- Number of participants with TEAEs leading to dose modification or discontinuationTime frame: Up to 2 years and 90 days
Locations
34 sites in 8 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona · Recruiting
Stanford University
Palo Alto, California · Recruiting
UCLA Healthcare Hematology-Oncology
Santa Monica, California · Recruiting
Sarah Cannon Research Institue At Healthone
Denver, Colorado · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, Maryland · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Weill Cornell Medicine
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Jefferson University Hospitals
Philadelphia, Pennsylvania · Recruiting
Scri Oncology Partners
Nashville, Tennessee · Recruiting
Md Anderson Cancer Center
Houston, Texas · Recruiting
Chris Obrien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
St Vincent'S Hospital Sydney
Darlinghurst, New South Wales, Australia · Recruiting
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Linear Clinical Research
Nedlands, Western Australia, Australia · Recruiting
Cliniques Universitaires Ucl Saint-Luc
Brussels, Belgium · Recruiting
Universitair Ziekenhuis Antwerpen (Uza)
Edegem, Belgium · Recruiting
Universitair Ziekenhuis (Uz) Leuven
Leuven, Belgium · Recruiting
The Ottawa Hospital Cancer Center
Ottawa, Ontario, Canada · Recruiting
Princess Margaret Cancer Center
Toronto, Ontario, Canada · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole
Toulouse, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy · Recruiting
Irccs Istituto Clinico Humanitas
Rozzano, Italy · Recruiting
Centro Ricerche Cliniche Di Verona
Verona, Italy · Recruiting
National Cancer Center Hospital East
Chiba, Japan · Recruiting
The Cancer Institute Hospital of Jfcr
Tokyo, Japan · Recruiting
Hospital General Universitario Vall D Hebron
Barcelona, Spain · Recruiting
Fundacion Jimenez Diaz
Madrid, Spain · Recruiting
Hospital Universitario Quironsalud Madrid
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.